You are here: Industry Insights > cancer drug

News List

BeiGene obtains certain rights for Leap Therapeutics’ cancer drug pharmaceutical-technology
January 07, 2020
Chinese biopharmaceutical firm BeiGene has agreed to exclusive rights to develop and commercialise Leap Therapeutics’ cancer drug DKN-01 in the Asia Pacific region, excluding Japan.
BeiGene cancer drug misses mark in Phase III study biospectrumasia
December 22, 2019
BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenström’s Macroglobulinemia
AstraZeneca’s Imfinzi cancer drug secures orphan status in US pharmaceutical-technology
July 17, 2019
The US Food and Drug Administration (FDA) has awarded orphan drug designation (ODD) to AstraZeneca’s Imfinzi (durvalumab) in small cell lung cancer (SCLC).
Evotec spin-off to develop cancer drugs using DDR pathway pharmaceutical-technology
July 10, 2019
Evotec has formed spin-off company Breakpoint Therapeutics to focus on the development of its DNA damage response (DDR) portfolio.
Roche wins Japan approval for personalised cancer drug Rozlytrek expresspharma
June 21, 2019
Swiss drugmaker Roche’s push into personalised cancer medicines hit a milestone with Japanese approval of a new drug, Rozlytrek, that targets patients who must be identified via genetic profiling.
Deciphera licenses cancer drug ripretinib to Zai Lab in China pharmaceutical-technology
June 13, 2019
US-based Deciphera Pharmaceuticals has signed an exclusive licence agreement with biopharmaceutical company Zai Lab to develop and commercialise cancer therapeutic ripretinib in Greater China.
Sandoz signs cancer drug deal with EirGenix pharmaceutical-technology
May 05, 2019
Sandoz has signed an agreement with EirGenix for the commercialisation of a trastuzumab biosimilar.
AstraZeneca signs major cancer drug deal bbc
April 18, 2019
British pharmaceutical giant AstraZeneca has signed a deal with Japanese firm Daiichi Sankyo to help develop and sell the cancer drug trastuzumab deruxtecan.
WuXi AppTec hires cancer drug development vet as new CMO fiercepharma
April 14, 2019
WuXi AppTec has hired Frederick Hausheer, M.D., as its new chief medical officer as it looks to mine his clinical trial expertise for its boosted drug development offerings.
Advisers urge FDA to delay decision on Karyopharm cancer drug pharmaphorum
February 28, 2019
Advisers to the US drugs regulator have said a decision on whether to approve Karyopharm’s multiple myeloma combination should be delayed until the results of a phase 3 trial, due late this year or in 2020.

Previous page 1 2 3 4 5 6 Next page